"The population is adult patients, 18 to 80 years of age, with NYHA class III/IV symptoms of heart failure due to ischemic or non-ischemic cardiomyopathy, and who, despite maximal optimized heart failure therapy regimens, are at high risk of heart failure-related hospitalizations. A total of 250 patients (N= ~125 per treatment arm) were enrolled for the purpose of obtaining at least 186 adjudicated heart failure-related hospitalizations."
(Looks like it could be obvious when 186 rehospitilizations are reached that a vast majority will be the non-treatment arm), should be well before 2015?
looks like the author is about a year late on prices. That would give us $3305 Zinc in 2015.
I've dug a little on future mines to come on line in the next few years. Looks like 3 of the biggest 5 zinc mines in the world will be depleted in the within the next year. It also looks like nobody has anything close to those even in the planning stage and once planning has started expect 5 to 10 years before significant production will be seen.
If anyone can correct me on that please post.
Quick hard dips followed by rip your face off rallies. I honestly think the little guys trying to trade this are losing money. I'm guessing a couple of weeks into August and the long term investors will start to see where the real trend is in the stock price.
GLTA. Glad I know I suck at day trading and haven't tried day trading this one.
See "Medpage Today"
Prediction Update: Dermatology (guess what the Doctor selected as the biggest news for 2014 to date) Picosure.
You have to register as a doctor to hear the review. It's an impressive site and an impressive review of what Picosure is doing for tattoo removal, a service that is growing at extreme rate. Some tattoos can be removed in 3 to 5 appointments versus 15 plus plus plus for many other lasers.
Also check "RealSelf" and look under tattoo removal to see what actual people are saying about Picosure tattoo removal versus what they have experienced with other lasers.
Zinc Price Forecast
Indeed, these junior companies are bound to be in focus over the medium term, with zinc prices expected to take off in 2016. CRU International forecasts that the real three-month price of zinc, defined as the nominal price/US consumer price index, will go from US$2,125 in 2012, to US$2,455 in 2015, and US$3,305 in 2016.
The nominal three-month price per pound is expected to go up to 161 cents in 2016 from 96.4 cents per pound in 2012.
(nice accuracy from 2012, buy the dips and hold for the long term) GLTA
Aticle very high on the new low cost Mooresboro NC plant ramping up with cost expected around 40 to 50 cents per pound.
Best you can do now is 80 cents out of ground and those cheaper mines are going out of business. Where will the stock price be by the fourth quarter of '14, 30 plus.
April 24, 2014 7:09 pm
...Several large mines, including Century in Australia and Lisheen in Ireland are expected to shut in 2015.
“Over a three-year period commencing last year, approximately 1.5m tonnes of current zinc production will be closed due to mine depletion. This is a significant figure in a 13m tonne market,” said chief executive Don Lindsay on a call with analysts.
So many "me too" drugs that do the same thing and one will be made in US. Which drug should be designated preffered drug on US formularies? The US citizens will make sure the business you developed by charging US customers up to 10 times what other countries pay doesn't take this lying down.
Are investors selling hoping buy back after lockup expiration date?
Are there day traders playing with this stock still trying to make money on a daily bounce?
How low do you guys think this one can go? No volume makes me think we are seeing artificial prices reached by the boys trading between each other to see if they can cause a panic sell into a spiral?
GLTA, would love more at lower prices
What did the FDA have to see before giving BreakThrough status:
"This designation is intended to expedite the development and review of drugs for serious or life-threatening conditions and where (((preliminary clinical evidence suggests it provides a substantial improvement over existing therapies)))."
First drug trial where I've seen an SPA that set the primary point as Readmissions. Looks like the FDA looked at the updated 3 year results on the high dose patients and were convinced that Mydicar has the potential to save billions of $ in health care costs every year. And, approved (SPA) readmissions as a primary endpoint.
Found an interesting article:
A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8
"we showed that after 1–5 PPs performed in a short period of time, NAF specific for AAV2, 1, 6, and 8 became undetectable for some patients when initial titers at the screening steps were ≤1:20. Furthermore, it was also possible to reduce the NAF titer to 1:5–1:2 but also for patients with low initial titers (≤1:20). Overcoming these residual NAF can be achieved by increasing vector dose, as previously described."
If you were aware of that information and you were talking to BIG Pharma about Mydicar would you sell the rights before a Plasmapheresis trial had the potential to add billion more to the sell price
It's a multibillion dollar drug if it improves on decreasig readmission rates if given at highest dose. Mydicar was able to reduce readmission rates for six months at the lower dose levels.
(Is this latest trial to makes sure you can't treat the additional 60% and get a $10B buyout price)
Piced up more at $12.50, thanks yall'
My hope for the lockup is that there are enough anxious sellers to create some cheap shares to be bought by long term buyers.
I'm comfortable with my holding but would love to pick up more shares at a cheaper price
First Cupid trial, many years ago:
"Only patients with undetectable neutralizing antibodies against AAV1 (titer
Was Mydicar the first "Breakthrough" that looked at a totally new type of therapy and say it should be given every opportunity to speedily move through the review process for the billions it could save our nations medical bill yearly? In addition to the fact that it has the potential to greatly improve the quality of the patients life.
FDA takes a close look at early data and grants "Breakthrough therapy" and agrees to an SPA that gives approval on basis of how soon a patient needs to be hospitalized post treatment.
expect dilution at $30 plus
Nothing should go wrong. Treated patients don't need to revisit the hospital after Mydicar treatment, unless the patient was too far gone at initiation.
Would love to see Celladon do another stock offer 5 millions shares at $30 partner off his product and take on the pulmonary indication. Would like a billion upfront. By the end of summer everyone running a trial site will have a very good idea why they have an arm of strong responders where there cardiac failure isn't spiraling to ever worse levels.
More leaks every week.
This one is going to save billions in health care dollars yearly.
Agree on possible buyout.
June 2, 2014
New CFO Paul Cleveland:
was Executive Vice President of Corporate Strategy and Chief Financial Officer of Aragon Pharmaceuticals, Inc. Aragon was sold to Johnson & Johnson in August 2013 for $1 billion.